1 (549c6214 D56a 48e7 Ac76 725908eea67b 01)
Alendronate Sodium Tablet
Product Images NDC 68071-3340
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Alendronate Sodium (NDC 68071-3340). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Nucare Pharmaceuticals,inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
2 (549c6214 D56a 48e7 Ac76 725908eea67b 02)
The text represents a graph showing the cumulative incidence of hip fractures in a study of FIT over a 3-year period. The study includes patients who had radiographic vertebral fractures at baseline and compares the results between placebo and alendronate sodium treatments. The x-axis of the graph is labeled as "time (months)" and the y-axis is labeled as "cumulative incidence (%)."*
3 (549c6214 D56a 48e7 Ac76 725908eea67b 03)
This is a table presenting the results of a study on the treatment of osteoporosis in postmenopausal women using Alendronate Sodium at a dosage of 10 mg/day for three years. The table shows the increase in bone mineral density (BMD) in various areas of the body, including the lumbar spine, femoral neck, and trochanter.*
4 (549c6214 D56a 48e7 Ac76 725908eea67b 04)
5 (549c6214 D56a 48e7 Ac76 725908eea67b 05)
This data appears to be a table or chart displaying a change in bone mineral density (BMD) in postmenopausal women over a 2-year and 3-year study. The BMD change is shown for different areas of the body, including the lumbar spine, femoral neck, and trochanter. There is also information about the amount of sodium ingested per day, but it is unclear how this information relates to the BMD data.*
6 (549c6214 D56a 48e7 Ac76 725908eea67b 06)
7 (549c6214 D56a 48e7 Ac76 725908eea67b 07)
This is a study that compares the effects of Alendronate Sodium 40 mg/day versus placebo or Etidronate 400 mg/day on serum alkaline phosphatase in Paget's disease of bone. The study involved 27 individuals and presents data in a graph showing the mean % change from baseline in serum alkaline phosphatase over time (in months) for each treatment group.*
68071 3340 4
uCare Pharmaceuticals is a manufacturer of Alendronate Sodium 70mg tablets, with NDC numbers 68071-3340-4 and 63071-3340-04. The tablets come in 4-tablet blister packs and the lot numbers are 000000. The medication's expiration date is 00-00. The label warns to keep the medication out of reach of children and to store it at a controlled temperature between 59-86°F. The manufacturer suggests consulting a doctor for medical advice about side effects and that side effects can be reported to the FDA.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
